[딜사이트 엄주연 기자] Samsung Bioepis recorded good performance in the first quarter thanks to increased sales of new products. The company expects annual sales to grow by up to 30% this year, driven by milestone revenues.
Samsung Bioepis announced on the 24th that its sales in the first quarter of this year were 280.1 billion won, a 31.3% increase over the previous year. During the same period, operating profit increased 5.5% to 38.1 billion won, and net profit also increased 66.1% to 45.5 billion won.
The increase in sales of new products played a major role in this good performance. As sales of biosimilar products increased in overseas markets such as the U.S. and Europe, both top-line growth and profitability improved.
Samsung Bioepis has 11 types of biosimilar products and pipelines. Seven types of products, including Enbrel biosimilar (SB4) and Humira biosimilar (SB5), are being sold in the global market.
The company expects growth to continue this year. This is because milestone profits are expected as the pipeline is approved in major regions. Accordingly, annual sales are expected to grow by 25-30%.
Samsung Bioepis plans to speed up clinical trials as well. The biosimilar (SB27) of the cancer immunotherapy drug ‘Keytruda’ is accelerating clinical trials through an ‘overlap’ strategy that conducts global phase 1 and 3 clinical trials simultaneously. In addition, we plan to develop five additional private pipelines.
A Samsung Bioepis official said, “We will solidify our position as a leading company in the biosimilar industry by obtaining product approval for a number of biosimilar products,” and added, “We will maintain continuous growth within the year through approval and launch of follow-up products.” .
Meanwhile, Samsung Bioepis recently became the first domestic company to receive product approval for its Stelara biosimilar (SB17) from the European Commission (EC). In Korea, rare blood disease treatment ‘Episcli (Soliris biosimilar, SB12)’, eye disease treatment ‘Apilibu’ (Eylea biosimilar, SB15), and autoimmune disease treatment ‘Epistech’ (Stella Product approval for LA biosimilar, SB17) was approved.
Reporter Eom Joo-yeon [email protected]
ⓒLooking at the market with new eyes. Deal site unauthorized reproduction prohibited
